Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment
Sintesi DuoBiz · · 2 min di lettura
Di cosa si tratta
Mironid, a Glasgow-based biopharmaceutical company, has closed a €39.9 million ($46 million) Series B financing round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. The round was led by Scottish National Investment Bank, which joined a syndicate of existing backers including Roche Venture Fund, Epidarex Capital, Sofinnova […] The post Glasgow-based Mironid raises €39.9 million in Series B to advance rare kidney disease treatment appeared first on EU-Startups .
Fonte: EU-Startups
